Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Bacterial Load and Molecular Markers Associated With Early-onset Group B Streptococcus

A Systematic Review and Meta-analysis

Seedat, Farah, PhD*; Brown, Colin Stewart, FRCPath; Stinton, Chris, PhD*; Patterson, Jacoby, MD*; Geppert, Julia, PhD*; Freeman, Karoline, MSc*; Tan, Bee, FRCS*; Johnson, Samantha Ann, MA*; Fraser, Hannah, BSc*; Uthman, Olalekan A., PhD*; Robinson, Esther R., BMBCh DPhil; McCarthy, Noel Denis, MB Dphil*; Clarke, Aileen, MD*; Taylor-Phillips, Sian, PhD*

The Pediatric Infectious Disease Journal: December 2018 - Volume 37 - Issue 12 - p e306–e314
doi: 10.1097/INF.0000000000002050
Maternal-Neonatal Reports
Buy
SDC

Background: The natural history of neonatal group B Streptococcus (GBS) is poorly understood. Little is known about the bacterial factors influencing the transmission of GBS from mother to neonate, or the development of invasive early-onset GBS disease (EOGBS) in colonized neonates. We reviewed whether bacterial load and molecular markers are associated with GBS vertical transmission and progression to EOGBS.

Methods: We searched Medline, Embase, Cochrane and Web of Science from inception to October 10, 2016, for observational studies in English. We also hand-searched reference lists of relevant publications and experts cross-checked included studies. Two reviewers independently screened studies, extracted data and appraised the quality of included studies using the Quality in Prognosis Studies tool. We conducted random-effects meta-analyses where possible and narratively synthesized the evidence in text and tables.

Results: Seventeen studies were included from 1107 records retrieved from electronic databases and publication references. Meta-analyses of 3 studies showed that neonates colonized by serotype III had a higher risk of developing EOGBS than serotype Ia (pooled risk ratio: 1.51, 95% confidence interval: 1.12–2.03) and serotype II (risk ratio: 1.95, 95% confidence interval: 1.10–3.45). Eleven studies showed that in heavily colonized mothers, 2–3 times more neonates were colonized, and in heavily colonized neonates, up to 15 times more neonates had EOGBS, compared with light colonization. Most evidence was published before 2000 and was at risk of bias.

Conclusions: Acknowledging the difficulty of natural history studies, well-controlled studies are needed to assess the predictive value of pathogen subtype and heavy load; they may be useful for better-targeted prevention.

From the *Division of Health Sciences, Warwick Medical School, University of Warwick, Gibbet Hill Campus, Coventry, United Kingdom

Bacteria Reference Department, National Infection Service, Public Health England, London, England

Field Service, National Infection Service, Public Health England, Seaton House, Nottingham.

Accepted for publication January 14, 2018.

Supported by the UK National Screening Committee (NSC). S.T.-P., A.C., C.S. and H.F. are supported by the National Institute of Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands. The views expressed in this publication are those of the authors and are not necessarily those of the NHS, NIHR or UK NSC.

The authors have no conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).

Address for correspondence: Sian Taylor-Phillips, PhD, Division of Health Sciences, University of Warwick Medical School, Gibbet Hill Campus, Coventry CV4 7AL, United Kingdom. E-mail: S.Taylor-Phillips@warwick.ac.uk.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.